Spark Therapeutics
-
MedCity INVEST Precision Medicine spotlight: Building a BioInnovation Hub (video)
The panel, What It Takes To Build A Successful, Regional BioInnovation Hub (sponsored by Independence Blue Cross) focuses on Philadelphia — one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries.
-
Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11
Here’s a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
A snapshot of the precision medicine landscape
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
-
Roche completes acquisition of Spark Therapeutics as regulators give go-ahead
The Federal Trade Commission and its U.K. counterpart concluded that Roche would not likely have an incentive to delay or discontinue development of Spark’s hemophilia A gene therapy. Roche markets a monoclonal antibody for the same disease.
-
Senators urge greater FTC scrutiny over large biopharma mergers
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
-
Cigna creates new program to pay for high-price gene therapies
The payer unveiled Embarc Benefit Protection, which it said would enable plans to pay a monthly, per-member fee to enroll, while patients would not have to pay anything out of pocket.
-
How best to describe precision medicine beyond oncology? ‘It’s complicated.’
While well-developed in cancers, precision medicine’s readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
-
Installment payments could be used across gene therapy space, Spark CEO says
In a fireside chat at the recently concluded Veeva Summit in Philadelphia, Jeff Marrazzo said payment over time is important for gene therapies, but the pace of policy making by government is too slow.
-
A Philadelphia story: Read about this gene therapy company’s journey from spinout to acquisition
A company’s journey from launch to acquisition is rarely a straight path. It involves overcoming many challenges and obstacles, especially for a pioneering gene therapy company. In this special report, Spark Therapeutics’ journey offers some interesting insights into the evolution of a life science business and how it finds an exit.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Biogen to acquire gene therapy company Nightstar Therapeutics for $800M
The biotech company said the deal would allow it to strengthen its ophthalmology pipeline. It follows last week’s acquisition of Spark Therapeutics by Roche for $4.8 billion.
-
Roche to buy Spark Therapeutics for $4.8 billion
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
-
Industry execs forecast the year ahead for gene therapy at Biotech Showcase
Hospitals – especially in Europe – anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
-
Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe
The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK’s NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.
-
Novartis, Spark make positive step toward gene therapy Luxturna’s European approval
With a positive CHMP decision, the European Commission is expected to rule in two months, but equity research analysts foresee significant headwinds for the gene therapy.